Antithrombotic therapy: standard therapy in essential hypertension?
Lip
Gregory Y H
GY
University Department of Medicine, City Hospital, Birmingham, England, UK. g.y.h.lip@bham.ac.uk
D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D009203:Myocardial Infarction / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D020521:Stroke / Q000517:prevention & control; D006113:United Kingdom; D014481:United States; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin; D001241:Aspirin